FFC#28/2015

Cystic fibrosis and meconium ileus: a multicentric study on risk factors for adverse outcome in infancy

FFC#28/2015

Cystic fibrosis and meconium ileus: a multicentric study on risk factors for adverse outcome in infancy

PRINCIPAL INVESTIGATOR

Rita Padoan (Centro di Supporto per fibrosi cistica – Università di Brescia, Ospedale dei Bambini, Azienda Ospedaliera Spedali Civili, Brescia)

RESEARCHERS

26

CATEGORY

AREA 5 Clinical and Epidemiological research

DURATION

2 years

GOAL

€ 55.000 €

RESULTS

The survey included 85 infants born with meconium ileus (MI) in 13 Italian centers, in the years 2009-2014. They represent 70% (85/121) of the reported cases in Italy during the same time-frame as per CF national register. In 20 infants (24%) the diagnosis of intestinal obstruction was also made possible through fetal ultrasound at the third trimester of pregnancy. Most cases (84%) went through surgery, which involved an intestinal resection and the creation of a transient stoma. In 18% of the infants, further abdominal surgery within the first month of life was necessary due to surgical complications.
Clinical data during the first year of life were collected and analysed. They showed in 37% of the patients a poor clinical evolution, characterized by insufficient nutritional status or by chronic Pseudomonas infection (22 children underweight and 9 with colonization from Pseudomonas). Factors identified as related to negative evolution were prenatal diagnosis through fetal ultrasound (pointing out the severity of the intestinal obstruction), the need for intensive care hospitalization, the use of oxygen therapy (sign of postoperative adverse conditions and rapid pulmonary involvement). Since the diagnosis of cystic fibrosis was not available at an early stage (it occurred at the age of 31 days, on average) and the advice from the CF specialist occurred during the first hospitalization only in a small number of cases, this study indicates the need for an immediate and close cooperation between neonatologists, surgeons and CF specialists.

OTHER RESULTS

FFC #3/2024

Two molecules are effective in activating Heat Shock Proteins and enhancing the action of CFTR correctors with the F508del mutation in vitro.

FFC#5/2024

Some peptide nucleic acids (PNAs) re-sensitise Pseudomonas aeruginosa to the antibiotic meropenem in vitro and reduce its virulence.

FFC#1/2023

Tezacaftor, one of the components of Kaftrio, induces an accumulation of dihydroceramides both in vitro and in vivo in animal models